Jump to content

EPAS1

From Wikipedia, the free encyclopedia
(Redirected from Hif2a)

EPAS1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesEPAS1, ECYT4, HIF2A, HLF, MOP2, PASD2, bHLHe73, endothelial PAS domain protein 1, Hypoxia-inducible factor-2alpha
External IDsOMIM: 603349; MGI: 109169; HomoloGene: 1095; GeneCards: EPAS1; OMA:EPAS1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

2034

13819

Ensembl

ENSG00000116016

ENSMUSG00000024140

UniProt

Q99814

P97481

RefSeq (mRNA)

NM_001430

NM_010137

RefSeq (protein)

NP_001421

NP_034267

Location (UCSC)Chr 2: 46.29 – 46.39 MbChr 17: 87.06 – 87.14 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Endothelial PAS domain-containing protein 1 (EPAS1, also known as hypoxia-inducible factor-2alpha (HIF-2α)) is a protein that is encoded by the EPAS1 gene in mammals. It is a type of hypoxia-inducible factor, a group of transcription factors involved in the physiological response to oxygen concentration.[5][6][7][8] The gene is active under hypoxic conditions. It is also important in the development of the heart, and for maintaining the catecholamine balance required for protection of the heart. Mutation often leads to neuroendocrine tumors.

However, several characterized alleles of EPAS1 contribute to high-altitude adaptation in humans.[9][10] One such allele, which has been inherited from Denisovan archaic hominins, is known to confer increased athletic performance in some people, and has therefore been referred to as the "super athlete gene".[11]

Function

[edit]

The EPAS1 gene encodes one subunit of a transcription factor involved in the induction of genes regulated by oxygen, and which is induced as oxygen concentration falls (hypoxia). The protein contains a basic helix-loop-helix protein dimerization domain as well as a domain found in signal transduction proteins which respond to oxygen levels. EPAS1 is involved in the development of the embryonic heart and is expressed in endothelial cells that line the walls of blood vessels in the umbilical cord.

EPAS1 is also essential for the maintenance of catecholamine homeostasis and protection against heart failure during early embryonic development.[8] Catecholamines regulated by EPAS1 include epinephrine and norepinephrine. It is critical that the production of catecholamines remain in homeostatic conditions so that both the delicate fetal heart and the adult heart do not overexert themselves and induce heart failure. Catecholamine production in the embryo is related to control of cardiac output by increasing the fetal heart rate.[12]

Alleles

[edit]

A high percentage of Tibetans carry an allele of EPAS1 that improves oxygen transport. The beneficial allele is also found in the extinct Denisovan genome, suggesting that it arose in them and entered the modern human population through hybridization.[13]

The Himalayan wolf[14] and the Tibetan mastiff[15] have inherited an altitude-adaptive allele of the gene from interbreeding with a ghost population of an unknown wolf-like canid. The EPAS1 allele is known to confer an adaptive advantage to animals living at high-altitudes.[14]

Clinical significance

[edit]

Mutations in the EPAS1 gene are related to early-onset neuroendocrine tumors such as paragangliomas, somatostatinomas and/or pheochromocytomas. The mutations are commonly somatic missense mutations that locate in the primary hydroxylation site of HIF-2α, which disrupt the protein hydroxylation/degradation mechanism, and leads to protein stabilization and pseudohypoxic signaling. In addition, these neuroendocrine tumors release erythropoietin (EPO) into circulating blood, and lead to polycythemia.[16][17]

Mutations in this gene are associated with erythrocytosis familial type 4,[8] pulmonary hypertension, and chronic mountain sickness.[18] There is also evidence that certain variants of this gene provide protection for people living at high altitude such as in Tibet.[9][10][19] The effect is most profound among the Tibetans living in the Himalayas at an altitude of about 4,000 metres above sea level, the environment of which is intolerable to other human populations due to 40% less atmospheric oxygen.

A study by UC Berkeley identified more than 30 genetic factors that make Tibetans' bodies well-suited for high-altitudes, including EPAS1.[20] Tibetans suffer no health problems associated with altitude sickness, but instead produce low levels of blood pigment (haemoglobin) sufficient for less oxygen, more elaborate blood vessels,[21] have lower infant mortality,[22] and are heavier at birth.[23]

EPAS1 is useful in high altitudes as a short term adaptive response. However, EPAS1 can also cause excessive production of red blood cells leading to chronic mountain sickness that can lead to death and inhibited reproductive abilities. Some mutations that increase its expression are associated with increased hypertension and stroke at low altitude, with symptoms similar to mountain sickness. Populations living permanently at high altitudes experience selection on EPAS1 for mutations which reduce the negative fitness consequences of excessive red blood cell production.[19]

Interactions

[edit]

EPAS1 has been shown to interact with aryl hydrocarbon receptor nuclear translocator[24] and ARNTL.[25]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000116016 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000024140 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Tian H, McKnight SL, Russell DW (January 1997). "Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells". Genes & Development. 11 (1): 72–82. doi:10.1101/gad.11.1.72. PMID 9000051.
  6. ^ Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, Perdew GH, Bradfield CA (March 1997). "Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway". The Journal of Biological Chemistry. 272 (13): 8581–93. doi:10.1074/jbc.272.13.8581. PMID 9079689.
  7. ^ Percy MJ, Beer PA, Campbell G, Dekker AW, Green AR, Oscier D, Rainey MG, van Wijk R, Wood M, Lappin TR, McMullin MF, Lee FS (June 2008). "Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis". Blood. 111 (11): 5400–2. doi:10.1182/blood-2008-02-137703. PMC 2396730. PMID 18378852.
  8. ^ a b c "Entrez Gene: EPAS1 endothelial PAS domain protein 1".
  9. ^ a b Yi X, Liang Y, Huerta-Sanchez E, Jin X, Cuo ZX, Pool JE, Xu X, Jiang H, Vinckenbosch N, Korneliussen TS, Zheng H, Liu T, He W, Li K, Luo R, Nie X, Wu H, Zhao M, Cao H, Zou J, Shan Y, Li S, Yang Q, Ni P, Tian G, Xu J, Liu X, Jiang T, Wu R, Zhou G, Tang M, Qin J, Wang T, Feng S, Li G, Luosang J, Wang W, Chen F, Wang Y, Zheng X, Li Z, Bianba Z, Yang G, Wang X, Tang S, Gao G, Chen Y, Luo Z, Gusang L, Cao Z, Zhang Q, Ouyang W, Ren X, Liang H, Zheng H, Huang Y, Li J, Bolund L, Kristiansen K, Li Y, Zhang Y, Zhang X, Li R, Li S, Yang H, Nielsen R, Wang J, Wang J (July 2010). "Sequencing of 50 human exomes reveals adaptation to high altitude". Science. 329 (5987): 75–8. Bibcode:2010Sci...329...75Y. doi:10.1126/science.1190371. PMC 3711608. PMID 20595611.
  10. ^ a b Hanaoka M, Droma Y, Basnyat B, Ito M, Kobayashi N, Katsuyama Y, Kubo K, Ota M (2012). "Genetic variants in EPAS1 contribute to adaptation to high-altitude hypoxia in Sherpas". PLOS ONE. 7 (12): e50566. Bibcode:2012PLoSO...750566H. doi:10.1371/journal.pone.0050566. PMC 3515610. PMID 23227185.
  11. ^ Algar J (1 July 2014). "Tibetan 'super athlete' gene courtesy of an extinct human species". Tech Times. Retrieved 22 July 2014.
  12. ^ Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL (November 1998). "The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development". Genes & Development. 12 (21): 3320–4. doi:10.1101/gad.12.21.3320. PMC 317225. PMID 9808618.
  13. ^ Jeong C, Alkorta-Aranburu G, Basnyat B, Neupane M, Witonsky DB, Pritchard JK, Beall CM, Di Rienzo A (2014-02-10). "Admixture facilitates genetic adaptations to high altitude in Tibet". Nature Communications. 5: 3281. Bibcode:2014NatCo...5.3281J. doi:10.1038/ncomms4281. PMC 4643256. PMID 24513612.
  14. ^ a b Wang MS, Wang S, Li Y, Jhala Y, Thakur M, Otecko NO, et al. (September 2020). "Ancient Hybridization with an Unknown Population Facilitated High-Altitude Adaptation of Canids". Molecular Biology and Evolution. 37 (9): 2616–2629. doi:10.1093/molbev/msaa113. PMID 32384152.
  15. ^ Miao B, Wang Z, Li Y (December 2016). "Genomic Analysis Reveals Hypoxia Adaptation in the Tibetan Mastiff by Introgression of the Grey Wolf from the Tibetan Plateau". Molecular Biology and Evolution. 34 (3): 734–743. doi:10.1093/molbev/msw274. PMID 27927792. S2CID 47507546.
  16. ^ Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT, Pacak K (September 2012). "Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia". The New England Journal of Medicine. 367 (10): 922–30. doi:10.1056/NEJMoa1205119. PMC 3432945. PMID 22931260.
  17. ^ Yang C, Sun MG, Matro J, Huynh TT, Rahimpour S, Prchal JT, Lechan R, Lonser R, Pacak K, Zhuang Z (March 2013). "Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas". Blood. 121 (13): 2563–6. doi:10.1182/blood-2012-10-460972. PMC 3612863. PMID 23361906.
  18. ^ Gale DP, Harten SK, Reid CD, Tuddenham EG, Maxwell PH (August 2008). "Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation". Blood. 112 (3): 919–21. doi:10.1182/blood-2008-04-153718. PMID 18650473.
  19. ^ a b Beall CM, Cavalleri GL, Deng L, Elston RC, Gao Y, Knight J, Li C, Li JC, Liang Y, McCormack M, Montgomery HE, Pan H, Robbins PA, Shianna KV, Tam SC, Tsering N, Veeramah KR, Wang W, Wangdui P, Weale ME, Xu Y, Xu Z, Yang L, Zaman MJ, Zeng C, Zhang L, Zhang X, Zhaxi P, Zheng YT (June 2010). "Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders". Proceedings of the National Academy of Sciences of the United States of America. 107 (25): 11459–64. Bibcode:2010PNAS..10711459B. doi:10.1073/pnas.1002443107. PMC 2895075. PMID 20534544.
  20. ^ Schaffer G (24 April 2014). "Five myths about Mount Everest". Washington Post. Retrieved 18 May 2019. – cites Sanders, Robert (July 1, 2010) Tibetans adapted to high altitude in less than 3,000 years, Mind & body, Research, Science & environment, Berkeley News
  21. ^ Beall CM (February 2006). "Andean, Tibetan, and Ethiopian patterns of adaptation to high-altitude hypoxia". Integrative and Comparative Biology. 46 (1): 18–24. CiteSeerX 10.1.1.595.7464. doi:10.1093/icb/icj004. PMID 21672719.
  22. ^ Beall CM, Song K, Elston RC, Goldstein MC (September 2004). "Higher offspring survival among Tibetan women with high oxygen saturation genotypes residing at 4,000 m". Proceedings of the National Academy of Sciences of the United States of America. 101 (39): 14300–4. doi:10.1073/pnas.0405949101. PMC 521103. PMID 15353580.
  23. ^ Beall CM (May 2007). "Two routes to functional adaptation: Tibetan and Andean high-altitude natives". Proceedings of the National Academy of Sciences of the United States of America. 104 (Suppl 1): 8655–60. doi:10.1073/pnas.0701985104. PMC 1876443. PMID 17494744.
  24. ^ Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, Perdew GH, Bradfield CA (March 1997). "Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway". The Journal of Biological Chemistry. 272 (13): 8581–93. doi:10.1074/jbc.272.13.8581. PMID 9079689.
  25. ^ Hogenesch JB, Gu YZ, Jain S, Bradfield CA (May 1998). "The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors". Proceedings of the National Academy of Sciences of the United States of America. 95 (10): 5474–9. Bibcode:1998PNAS...95.5474H. doi:10.1073/pnas.95.10.5474. PMC 20401. PMID 9576906.

Further reading

[edit]
[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=EPAS1&oldid=1252992674"